3.69
-0.13(-3.40%)
Currency In USD
| Previous Close | 3.82 |
| Open | 3.8 |
| Day High | 3.96 |
| Day Low | 3.6 |
| 52-Week High | 5.59 |
| 52-Week Low | 3.41 |
| Volume | 456,983 |
| Average Volume | 116,760 |
| Market Cap | 126.9M |
| PE | -3.29 |
| EPS | -1.12 |
| Moving Average 50 Days | 4.58 |
| Moving Average 200 Days | 4.66 |
| Change | -0.13 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $0.8 as of December 21, 2024 at a share price of $3.69. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $376.53 as of December 21, 2024 at a share price of $3.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer
GlobeNewswire Inc.
Dec 09, 2024 1:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment
Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA
GlobeNewswire Inc.
Dec 03, 2024 1:30 PM GMT
Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping CessationSEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutica
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 14, 2024 1:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment